Eculizumab for Pediatric Hematopoietic Cell Transplant-Associated Thrombotic Microangiopathy: Real-World Response Rates, Predictors of Poor Response, and an Optimal Time Point for Treatment Response Assessment.
Saved in:
| Title: | Eculizumab for Pediatric Hematopoietic Cell Transplant-Associated Thrombotic Microangiopathy: Real-World Response Rates, Predictors of Poor Response, and an Optimal Time Point for Treatment Response Assessment. |
|---|---|
| Authors: | Schoettler ML; Children's Healthcare of Atlanta, Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, Georgia. Electronic address: Michelle.Schoettler@emory.edu., Cheng G; Division of Pediatric Allergy, Immunology, and Bone Marrow Transplant, University of California San Francisco, Benioff Children's Hospitals, San Francisco, California., Higham CS; Division of Pediatric Allergy, Immunology, and Bone Marrow Transplant, University of California San Francisco, Benioff Children's Hospitals, San Francisco, California., Dvorak CC; Division of Pediatric Allergy, Immunology, and Bone Marrow Transplant, University of California San Francisco, Benioff Children's Hospitals, San Francisco, California., Rush C; Department of Pediatric Hematology, Oncology, Blood and Marrow Transplant, Nationwide Children's Hospital, Columbus, Ohio and Department of Pediatrics, The Ohio State University, Columbus, Ohio., Rangarajan HG; Department of Pediatric Hematology, Oncology, Blood and Marrow Transplant, Nationwide Children's Hospital, Columbus, Ohio and Department of Pediatrics, The Ohio State University, Columbus, Ohio., Al-Nazer M; Department of Pediatric Hematology, Oncology, Blood and Marrow Transplant, Nationwide Children's Hospital, Columbus, Ohio and Department of Pediatrics, The Ohio State University, Columbus, Ohio., Polishchuk V; Lurie Children's Hospital of Chicago, Chicago, Illinois., Chaudhury S; Lurie Children's Hospital of Chicago, Chicago, Illinois., Lehmann L; Boston Children's Hospital, Dana Farber Cancer Institute, Boston, Massachusetts., Duncan C; Boston Children's Hospital, Dana Farber Cancer Institute, Boston, Massachusetts., Nishitani M; Boston Children's Hospital, Dana Farber Cancer Institute, Boston, Massachusetts., Manougian H; Cleveland Clinic, Cleveland, Ohio., Rotz S; Cleveland Clinic, Cleveland, Ohio., Ofori J; Children's Healthcare of Atlanta, Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, Georgia., Frost E; Children's Healthcare of Atlanta, Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, Georgia., Orbodo J; Children's Healthcare of Atlanta, Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, Georgia., Spencer K; Children's Healthcare of Atlanta, Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, Georgia., Kenney E; Children's Healthcare of Atlanta, Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, Georgia., Chonat S; Children's Healthcare of Atlanta, Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, Georgia., Chewning J; Children's of Alabama, Birmingham, Alabama., Moore C; Children's of Alabama, Birmingham, Alabama., Westbrook A; Pediatric Biostatistics Core, Department of Pediatrics, Emory University, Atlanta, Georgia., Williams KM; Children's Healthcare of Atlanta, Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, Georgia. |
| Source: | Transplantation and cellular therapy [Transplant Cell Ther] 2026 Jul; Vol. 32 (7), pp. 887.e1-887.e16. Date of Electronic Publication: 2026 Apr 24. |
| Publication Type: | Journal Article; Multicenter Study; Observational Study |
| Journal Info: | Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101774629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-6367 (Electronic) Linking ISSN: 26666367 NLM ISO Abbreviation: Transplant Cell Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
